Longitudinal PET RANO 1.0 and RANO 2.0 response assessment in vorasidenib-treated IDH -mutant gliomas: the VORAFET study
Neuro-Oncology · 30.10.2026
DOI: 10.1093/neuonc/noag273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 30.10.2026. Verfasst von Giuseppe Lombardi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Conventional MRI may not fully reflect the biological activity of vorasidenib. PET may detect treatment-related metabolic changes before structural changes become evident on MRI. We evaluated longitudinal PET and MRI changes in patients with IDH-mutant gliomas receiving vorasidenib.
Methods
VORAFET is a longitudinal study of adults with IDH-mutant gliomas treated with vorasidenib. Eligible patients had predominantly non-enhancing WHO grade 2 or 3 gliomas, had not received prior radiotherapy or chemotherapy. The primary endpoint was longitudinal metabolic and structural imaging response according to PET RANO 1.0 and RANO 2.0. Integrated [¹⁸F]FET PET/MRI was performed at baseline and every 3 months.
Results
Thirty-nine patients were included; at baseline, 23 and 29 had PET and MRI-measurable disease. As best response, PET RANO 1.0 identified 2 complete and 12 partial responses, yielding an ORR of 60.9%; median time to first response was 4.5 months (range 3-12 months). RANO 2.0 showed no complete or partial responses, whereas 5 patients achieved minor response at a median of 9 months (range 6-12 months). Progressive disease occurred in 6 of 39 patients (15.4%) according to PET RANO 1.0 and in 1 of 39 (2.6%) according to RANO 2.0. Patients with PET-PD more often had subtle contrast enhancement and showed higher baseline FLAIR volume, MTV, TBRmax, and TBRmean.
Conclusions
PET RANO 1.0 identified metabolic changes during vorasidenib treatment that were not always reflected by RANO 2.0 assessment. Longer follow-up is needed to clarify the relationship between PET metabolic changes and MRI findings and to determine their clinical significance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
- Padova Neuroscience Center (PNC), University of Padova, Padova, Italy.
- Neuroradiology Unit, Padova University Hospital, Padova, Italy.
- Academic Neurosurgery, Department of Neurosciences, University of Padova, Padova, Italy.
- Independent statistician, Solagna, Italy.
Zitieren
APA
Lombardi, G., Bosio, A., Librizzi, G., Anglani, M., Ius, T., Caccese, M., Padovan, M., Cavallin, F., Maccari, M., Volpin, F., Pasqualetti, F., Simeone, R., Parisi, A., Salvalaggio, A., Bellu, L., Denaro, L., Lonardi, S., Preusser, M., Albert, N. L., & Cecchin, D. (2026). Longitudinal PET RANO 1.0 and RANO 2.0 response assessment in vorasidenib-treated IDH -mutant gliomas: the VORAFET study. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag273
Vancouver
Lombardi G, Bosio A, Librizzi G, Anglani M, Ius T, Caccese M, et al. Longitudinal PET RANO 1.0 and RANO 2.0 response assessment in vorasidenib-treated IDH -mutant gliomas: the VORAFET study. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag273
BibTeX
@article{Lombardi2026,
author = {Lombardi, Giuseppe and Bosio, Alberto and Librizzi, Giovanni and Anglani, Mariagiulia and Ius, Tamara and Caccese, Mario and Padovan, Marta and Cavallin, Francesco and Maccari, Marta and Volpin, Francesco and Pasqualetti, Francesco and Simeone, Rossella and Parisi, Alessandro and Salvalaggio, Alessandro and Bellu, Luisa and Denaro, Luca and Lonardi, Sara and Preusser, Matthias and Albert, Nathalie L and Cecchin, Diego},
title = {Longitudinal PET RANO 1.0 and RANO 2.0 response assessment in vorasidenib-treated IDH -mutant gliomas: the VORAFET study},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag273}
}
EUVIMED